Nivolumab: an investigational agent for the treatment of biliary tract cancer

References

• Lamarca A, Barriuso J, McNamara MG, et al. Molecular targeted therapies: ready for “prime time” in biliary tract cancer. J Hepatol. 2020;73(1):170–185.
   PubMed Web of Science ®Google Scholar
• Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020. DOI:10.1038/s41575-020-0310-z.
   PubMed Web of Science ®Google Scholar
• SEER. Cancer stat facts: liver and intrahepatic bile duct cancer. Bethesda, MD: National Cancer Institute. Available from: https://seer.cancer.gov/statfacts/html/livibd.html
   Google Scholar
• Rizzo A, Ricci AD, Tavolari S, et al. Circulating tumor DNA in biliary tract cancer: current evidence and future perspectives. Cancer Genomics Proteomics. 2020 Sep-Oct;17(5):441–452.
   PubMed Web of Science ®Google Scholar
• Jung SJ, Woo SM, Park HK, et al. Patterns of initial disease recurrence after resection of biliary tract cancer. Oncology. 2012;83(2):83–90. Epub 2012 Jul 9. PMID: 22777276.
   PubMed Web of Science ®Google Scholar
• Bridgewater JA, Goodman KA, Kalyan A, et al. Biliary tract cancer: epidemiology, radiotherapy, and molecular profiling. Am Soc Clin Oncol Educ Book. 2016;35:e194–203.
   PubMedGoogle Scholar
• Forner A, Vidili G, Rengo M, et al. Clinical presentation, diagnosis and staging of cholangiocarcinoma. Liver Int. 2019;39(Suppl1):98–107.
   PubMed Web of Science ®Google Scholar
• Valle JW, Wasan H, Johnson P, et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: A multicentre randomised phase II study- the UK ABC-01 study. Br J Cancer. 2009. Published online. DOI:10.1038/sj.bjc.6605211.
   PubMed Web of Science ®Google Scholar
• Valle J, Wasan H, Palmer DH, et al. ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273–1281.
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Tober N, et al. Second-line treatment in advanced biliary tract cancer: today and tomorrow. Anticancer Res. 2020;40(6):3013–3030.
   PubMed Web of Science ®Google Scholar
• Lamarca A, Palmer DH, Wasan HS, et al. ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced/metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy. J Clin Oncol. 2019. Published online. DOI:10.1200/jco.2019.37.15_suppl.4003.
   PubMed Web of Science ®Google Scholar
• Rizvi S, Khan SA, Hallemeier CL, et al. Cholangiocarcinoma ‐ evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018;15(2):95‐111.
   PubMed Web of Science ®Google Scholar
• Mizrahi JD, Shroff RT. New treatment options for advanced biliary tract cancer. Curr Treat Options Oncol. 2020;21(8):63.
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Brandi G. Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives. Expert Opin Investig Drugs. 2020 Oct;25:1–8.
   Google Scholar
• Massa A, Varamo C, Vita F, et al. Evolution of the experimental models of cholangiocarcinoma. Cancers (Basel). 2020 Aug 17;12(E):2308.
   Web of Science ®Google Scholar
• Athauda A, Fong C, Lau DK, et al. Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation. Cancer Treat Rev. 2020;86:101998.
   PubMed Web of Science ®Google Scholar
• Ricci AD, Rizzo A, Brandi G. Immunotherapy in biliary tract cancer: worthy of a second look. Cancer Control. 2020. Published online. DOI:10.1177/1073274820948047.
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, Kamgar M, Mahipal A. Targeted therapies in advanced biliary tract cancer: an evolving paradigm. Cancers (Basel). 2020 Jul 24;12(8):2039.
   PubMed Web of Science ®Google Scholar
• Hoy SM. Pemigatinib: first approval. Drugs. 2020;80(9):923–929.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020. Published online. DOI:10.1016/S1470-2045(20)30109-1.
   Web of Science ®Google Scholar
• Mazzaferro V, El-Rayes BF, Droz Dit Busset M, et al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. Br J Cancer. 2019;120:165–171.
   PubMed Web of Science ®Google Scholar
• Saha SK, Parachoniak CA, Ghanta KS, et al. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. Nature. 2014. Published online. DOI:10.1038/nature13441.
   Web of Science ®Google Scholar
• Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020. Published online. DOI:10.1016/S1470-2045(20)30157-1.
   Web of Science ®Google Scholar
• Robertson S, Hyder O, Dodson R, et al. The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome. Hum Pathol. 2013 Dec;44(12):2768–2773. Epub 2013 Oct 15. PMID: 24139215; PMCID: PMC3838441.
   PubMed Web of Science ®Google Scholar
• Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015. Published online. DOI:10.1056/nejmoa1502309.
   PubMed Web of Science ®Google Scholar
• Subbiah V, Puzanov I, Blay JY, et al. Pan-cancer efficacy of vemurafenib in brafv600-mutant non-melanoma cancers. Cancer Discov. 2020. Published online. DOI:10.1158/2159-8290.CD-19-1265.
   Web of Science ®Google Scholar
• Subbiah V, Lassen U, Élez E, et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 2020. Published online. DOI:10.1016/S1470-2045(20)30321-1.
   Web of Science ®Google Scholar
• Galdy S, Lamarca A, McNamara MG, et al. HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target? Cancer Metastasis Rev. 2017;36(1):141–157.
   PubMed Web of Science ®Google Scholar
• Javle M, Churi C, Kang HC, et al. HER2/neu-directed therapy for biliary tract cancer. J Hematol Oncol. 2015;8:58. Published 2015 May 29.
   PubMed Web of Science ®Google Scholar
• Javle MM, Hainsworth JD, Swanton C, et al. Pertuzumab + trastuzumab for HER2-positive metastatic biliary cancer: preliminary data from MyPathway. J Clin Oncol. 2017. Published online. DOI:10.1200/jco.2017.35.4_suppl.402.
   PubMed Web of Science ®Google Scholar
• Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018 Feb 8;554(7691):189–194. Epub 2018 Jan 31. Erratum in: Nature. 2019 Feb;566(7745):E11-E12. PMID: 29420467; PMCID: PMC5808581.
   PubMed Web of Science ®Google Scholar
• Valle JW, Lamarca A, Goyal L, et al. New horizons for precision medicine in biliary tract cancers. Cancer Discov. 2017;7(9):943–962. doi:10.1158/2159-8290.CD-17-0245. Epub 2017 Aug 17. PMID: 28818953; PMCID: PMC5586506..
   PubMed Web of Science ®Google Scholar
• Oneda E, Abu Hilal M, Zaniboni A. Biliary tract cancer: current medical treatment strategies. Cancers (Basel). 2020;12(5):1237.
   PubMed Web of Science ®Google Scholar
• Malenica I, Donadon M, Lleo A. Molecular and immunological characterization of biliary tract cancers: a paradigm shift towards a personalized medicine. Cancers (Basel). 2020;12:2190.
   Web of Science ®Google Scholar
• Kelley RK, Bridgewater J, Gores GJ, et al. Systemic therapies for intrahepatic cholangiocarcinoma. J Hepatol. 2020;72(2):353–363.
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–571.
   PubMed Web of Science ®Google Scholar
• Solomon B, Young RJ, Bressel M, et al. Prognostic significance of PD-L1+ and CD8+ immune cells in HPV+ oropharyngeal squamous cell carcinoma. Cancer Immunol Res. 2018;6(3):295–304.
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015. Published online. DOI:10.1056/NEJMoa1500596.
   Web of Science ®Google Scholar
• Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020. Published online. DOI:10.1016/S1470-2045(20)30445-9.
   Web of Science ®Google Scholar
• US Food and Drug Administration. FDA approves pembrolizumab for adults and children with TMB-H solid tumors. US Food and Drug Administration. 2020 June 17. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors
   Google Scholar
• Salem ME, Xiu J, Weinberg BA, et al. Characterization of tumor mutation burden (TMB) in gastrointestinal (GI) cancers. J Clin Oncol. 2017. Published online. DOI:10.1200/jco.2017.35.4_suppl.530.
   PubMed Web of Science ®Google Scholar
• Weinberg BA, Xiu J, Lindberg MR, et al. Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets. J Gastrointest Oncol. 2019. Published online. DOI:10.21037/jgo.2018.08.18.
   Web of Science ®Google Scholar
• Fontugne J, Augustin J, Pujals A, et al. PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma. Oncotarget. 2017;8:24644–24651.
   PubMedGoogle Scholar
• Bang Y-J, Ueno M, Malka D, et al. Pembrolizumab (pembro) for advanced biliary adenocarcinoma: results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies. J Clin Oncol. 2019. Published online. DOI:10.1200/jco.2019.37.15_suppl.4079.
   Web of Science ®Google Scholar
• Ahn S, Lee J, Shin DW, et al. High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer. Sci Rep. 2020;10:12348.
   PubMed Web of Science ®Google Scholar
• Arkenau H, Martin‐Liberal J, Calvo E, et al. Ramucirumab plus pembrolizumab in patients with previously treated advanced or metastatic biliary tract cancer: nonrandomized, open‐label, phase i trial (JVDF). Oncologist. 2018. Published online. DOI:10.1634/theoncologist.2018-0044.
   Web of Science ®Google Scholar
• Cho BC, Daste A, Ravaud A, et al. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase i cohort. J Immunother Cancer. 2020. Published online. DOI:10.1136/jitc-2020-000664.
   Web of Science ®Google Scholar
• Song X, Hu Y, Li Y, et al. Overview of current targeted therapy in gallbladder cancer. Signal Transduct Target Ther. 2020 Oct 7;5(1):230.
   PubMed Web of Science ®Google Scholar
• Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008. Published online. DOI:10.1146/annurev.immunol.26.021607.090331.
   PubMed Web of Science ®Google Scholar
• Wu Q, Jiang L, Li SC, et al. Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway. Acta Pharmacol Sin. 2020 Mar 9. Epub ahead of print. PMID: 32152439. DOI:10.1038/s41401-020-0366-x.
   Web of Science ®Google Scholar
• Scapin G, Yang X, Prosise WW, et al. Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab. Nat Struct Mol Biol. 2015. Published online. DOI:10.1038/nsmb.3129.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(36):2455–2465.
   PubMed Web of Science ®Google Scholar
• Fessas P, Lee H, Ikemizu S, et al. A molecular and preclinical comparison of the PD-1–targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab. Semin Oncol. 2017. Published online. DOI:10.1053/j.seminoncol.2017.06.002.
   PubMed Web of Science ®Google Scholar
• Wong RM, Scotland RR, Lau RL, et al. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen specific CTLs. Int Immunol. 2007;19(10):1223–1234.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent antiprogrammed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunogenic correlates. J Clin Oncol. 2010;28(19):3167–3175.
   PubMed Web of Science ®Google Scholar
• Picardo SL, Doi J, Hansen AR. Structure and optimization of checkpoint inhibitors. Cancers (Basel). 2019 Dec 21;12(1):38.
   Web of Science ®Google Scholar
• Tan S, Zhang H, Chai Y, et al. An unexpected N-terminal loop in PD-1 dominates binding by nivolumab. Nat Commun. 2017 Feb 6;8:14369.
   PubMed Web of Science ®Google Scholar
• Zak KM, Grudnik P, Magiera K, et al. Structural biology of the immune checkpoint receptor PD-1 and its ligands PD-L1/PD-L2. Structure. 2017 Aug 1;25(8):1163–1174.
   PubMed Web of Science ®Google Scholar
• Ueno M, Ikeda M, Morizane C, et al. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. Lancet Gastroenterol Hepatol. 2019. Published online. DOI:10.1016/S2468-1253(19)30086-X.
   PubMed Web of Science ®Google Scholar
• Kim RD, Chung V, Alese OB, et al. A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer. JAMA Oncol. 2020. Published online. DOI:10.1001/jamaoncol.2020.0930.
   Web of Science ®Google Scholar
• Klein O, Kee D, Nagrial A, et al. Evaluation of combination nivolumab and ipilimumab immunotherapy in patients with advanced biliary tract cancers: subgroup analysis of a phase 2 nonrandomized clinical trial. JAMA Oncol. 2020. Published online. DOI:10.1001/jamaoncol.2020.2814.
   Web of Science ®Google Scholar
• Gani F, Nagarajan N, Kim Y, et al. Program death 1 immune checkpoint and tumor microenvironment: implications for patients with intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2016;23:2610–2617.
   PubMed Web of Science ®Google Scholar
• Cao J, Hu J, Liu S, et al. Intrahepatic cholangiocarcinoma: genomic heterogeneity between Eastern and Western patients. JCO Precis Oncol. 2020 Jun 1;4:PO.18.00414. PMID: 32923885; PMCID: PMC7446410.
   PubMed Web of Science ®Google Scholar
• Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015;47:1003–1010.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet. 2016. Published online. DOI:10.1016/S0140-6736(15)01281-7.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015. Published online. DOI:10.1056/NEJMoa1507643.
   PubMed Web of Science ®Google Scholar
• Minchom A, Aversa C, Lopez J. Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies. Ther Adv Med Oncol. 2018 Jul 13;10:1758835918786658.
   Web of Science ®Google Scholar
• Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N Engl J Med. 2019 Nov 21;381(21):2020–2031.
   PubMed Web of Science ®Google Scholar
• Spizzo G, Puccini A, Xiu J, et al. Molecular profile of BRCA-mutated biliary tract cancers. ESMO Open. 2020. Published online. DOI:10.1136/esmoopen-2020-000682.
   Web of Science ®Google Scholar
• Lamarca A, Barriuso J, McNamara MG, et al. Biliary tract cancer: state of the art and potential role of DNA damage repair. Cancer Treat Rev. 2018 Nov;70:168–177.
   PubMed Web of Science ®Google Scholar
• Ricci AD, Rizzo A, The BG. DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora’s box? ESMO Open. 2020;5:e001042.
   PubMed Web of Science ®Google Scholar
• Wang Z, Sun K, Xiao Y, et al. Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models. Sci Rep. 2019. Published online. DOI:10.1038/s41598-019-38534-6.
   Web of Science ®Google Scholar
• Lamberti G, Andrini E, Sisi M, et al. Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: rationale and clinical implication. Futur Oncol. 2020. Published online. DOI:10.2217/fon-2020-0215.
   PubMed Web of Science ®Google Scholar